SavedAdd your journal

Journals / Turkish Journal of Cancer / 2003 / Cilt: 33 - Sayı: 4

Gemcitabine and cisplatin in the treatment of patients with locally advanced and metastatic pancreatic carcinoma

Mustafa ALTINBAŞ
METİN ÖZKAN
Hasan Şenol COŞKUN
Bünyamin KAPLAN
Can KÜÇÜK
Fevzi ALTUNTAŞ
Bülent ESER
Pages
181–186
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The median overall survival was 7±0.9 months (95% Cl, 5.3-8.7) with 61% and 21% of patients alive at 6 and 12 months, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This study was conducted to determine the efficacy and toxicity of gemcitabine in combination with cisplatin in patients with advanced pancreatic carcinoma.
📊
Key Findings & Data:The drug schedule included gemcitabine 800 mg/m2 administered on day 1 and 8 of each cycle and cisplatin 75 mg/m2 on day 1 or 2 every 3 weeks.
💡
Conclusion & Impact:The median overall survival was 7±0.9 months (95% Cl, 5.3-8.7) with 61% and 21% of patients alive at 6 and 12 months, respectively.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İlaç toksisitesi · Sisplatin · Deoksisitidin

Abstract

This study was conducted to determine the efficacy and toxicity of gemcitabine in combination with cisplatin in patients with advanced pancreatic carcinoma. The drug schedule included gemcitabine 800 mg/m2 administered on day 1 and 8 of each cycle and cisplatin 75 mg/m2 on day 1 or 2 every 3 weeks. Twenty-eight patients were registered on this study. The objective response rate was 14%. One of these had complete response (3%) and 3 patients had partial response (11%). Eight patients had stable disease (29%) and the clinical benefit was obtained at 12 patients (43%). The median time to progression in the study was 5±0.5 months (95% Cl, 4.0-6.0), with 36% of patients progression free at 6 months. The median overall survival was 7±0.9 months (95% Cl, 5.3-8.7) with 61% and 21% of patients alive at 6 and 12 months, respectively. Gemcitabine and cisplatin combination is moderately effective and toxicity of this schedule is tolerable in these advanced pancreatic carcinoma patients.

🔖

Cite This Article

ALTINBAŞ, M., ÖZKAN, M., COŞKUN, H. Ş., KAPLAN, B., KÜÇÜK, C., ALTUNTAŞ, F., ESER, B. (2003). Gemcitabine and cisplatin in the treatment of patients with locally advanced and metastatic pancreatic carcinoma. Turkish Journal of Cancer, Cilt: 33 - Sayı: 4, 181–186. https://ajindex.com/articles/368481

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. McKenna S, Eatock M. The Medical Management of Pancreatic Cancer: A Review. The Oncologist 2003;8:149-60
  2. Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81:882-5
  3. Glimelius B, Hoffmann K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600
  4. Carmichael J. The role of gemcitabine in the treatment of other tumors. Br J Cancer 1998;78(3 Suppl):21-5
  5. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13
  6. Rothenberg ML, Moore MJ, Cripps MC, et al. A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-53
  7. Einhorn LH. Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol 1997;24(3 Suppl 8):S8
  8. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomised Phase III study of gemcitabine-cisplatin in the treatment of locally advanced or metastatic non small cell lung cancer. J Clin Oncol 1991;17:12-8
  9. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18:1921-7
  10. Kanzawa F, Saijo N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 1997;24(2 Suppl 7):S7
  11. Bergman AM, Ruiz van Haperen VWT, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521-30
  12. Peters GJ, Ruiz van Haperen VW, Bergman AM, et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 1996;23(5 Suppl 10):16- 24
  13. Lund B, Neijt JP. Gemcitabine in cisplatin-resistant ovarian cancer. Semin Oncol 1996;23(5 Suppl 10):72-6
  14. Waud WR, Gilbert KS, Grindey GB, et al. Lack of in vivo cross-resistance with gemcitabine against drug-resistant murine P388 leukemias. Cancer Chemother Pharmacol 1996; 38:178-80
  15. Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine. Results for over 3000 patients with pancreatic carcinoma. Cancer 1999;85:1261-8
  16. Cascinu S, Silva RR, Barni S, et al. A combination of gemcitabine and 5-fl